Francisco D. Salva
President, CEO & DirectorMr. Francisco D. Salva serves as President, Chief Executive Officer and Director at Azitra Inc. since April 2021. He was an Independent Director at Vincerx Pharma, Inc. (formerly known as Vincera Pharma, Inc) since December 2020 until June 30, 2025. He was a Director with CIBC Capital Partners' Venture Group. He is an Operating Partner at Accelerator Life Science Partners since January 2018. He served as President, Chief Executive Officer and Director of Complexa Inc. since May 2018 until August 2020. He is founder of Acerta Pharma B.V. During his tenure at Acerta Pharma, he built a company from the ground up, advanced a leading oncology product and executed on numerous financings and industry deals. Mr. Salva joined CIBC in 2001 and focused on healthcare venture capital investments, primarily in the biotechnology, medical devices and healthcare IT industries. Previously, he served as Director of Private Equity at INVESCO Funds Group, where he was responsible for all private healthcare investments. Mr. Salva began his venture career in the healthcare group of Patricof & Co. Ventures with prior experience as an investment banker in the healthcare M&A group of Wasserstein Perella. Mr. Salva has experience in biotechnology finance, venture capital and operating roles. He co-founded Acerta Pharma BV and served as its Vice President of Operations from February 2013 to November 2016. where he focused on key growth initiatives by AstraZeneca for a controlling ownership interest. While at Acerta Pharma, Mr. Salva was responsible for the company’s financial and operational activities. His responsibilities included deal analysis and negotiations, investor relationships, partnership compliance and financings. Earlier in his career, Mr. Salva spent almost a decade as a life sciences venture capitalist at CIBC Capital Partners, INVESCO Funds Group and Patricof & Co. Ventures. He began his career at Wasserstein Perella & Co. Prior to Acerta, he served as Senior Director of Corporate Finance at Pharmacyclics, where he participated in the strategic turnaround of the company that reprioritized focus and efforts on ibrutinib. Mr. Salva earned his MSc. in Economics and philosophy from the London School of Economics and graduated magna cum laude with a double A.B. in Business Economics and Philosophy from Brown University.
Positions
- Company NameAzitra, Inc.Stock CodeAZTRPositionPresident, CEO & Director
